Ritter Pharmaceuticals (NASDAQ:RTTR) Lowered to “Hold” at Zacks Investment Research

Zacks Investment Research lowered shares of Ritter Pharmaceuticals (NASDAQ:RTTR) from a buy rating to a hold rating in a research report sent to investors on Wednesday, Zacks.com reports.

According to Zacks, “Ritter Pharmaceuticals, Inc. is involved in developing therapeutic products to treat inflammatory, gastrointestinal and metabolic diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which is under development for the reduction of symptoms associated with lactose intolerance. Ritter Pharmaceuticals, Inc. is headquartered in Los Angeles, California. “

Separately, ValuEngine lowered shares of Zumiez from a hold rating to a sell rating in a report on Tuesday, July 2nd.

Ritter Pharmaceuticals stock opened at $0.99 on Wednesday. The business’s 50-day moving average price is $0.96. Ritter Pharmaceuticals has a 1-year low of $0.47 and a 1-year high of $2.56.

Ritter Pharmaceuticals (NASDAQ:RTTR) last posted its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.58) earnings per share for the quarter, topping the Zacks’ consensus estimate of ($0.72) by $0.14. As a group, research analysts predict that Ritter Pharmaceuticals will post -1.3 EPS for the current year.

A hedge fund recently bought a new stake in Ritter Pharmaceuticals stock. Virtu Financial LLC bought a new position in shares of Ritter Pharmaceuticals Inc (NASDAQ:RTTR) in the first quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor bought 52,426 shares of the biotechnology company’s stock, valued at approximately $46,000. Virtu Financial LLC owned 0.91% of Ritter Pharmaceuticals at the end of the most recent quarter. Institutional investors own 6.29% of the company’s stock.

About Ritter Pharmaceuticals

Ritter Pharmaceuticals, Inc develops and sells novel therapeutic products that modulate the human gut microbiome to treat gastrointestinal diseases. Its lead product candidate is RP-G28, a novel microbiome modulator, which has completed Phase 2b clinical trial for the reduction of symptoms associated with lactose intolerance.

Featured Story: Hedge Funds

Get a free copy of the Zacks research report on Ritter Pharmaceuticals (RTTR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Ritter Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ritter Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.